Advertisement

Pharmacy

In response to criticism over the escalating prices of insulin, Danish drugmaker Novo Nordisk announced two programs to help lower the cost of the drug for U.S. diabetic patients. 

Mallinckrodt has agreed to pay $15.4 million to resolve whistleblower allegations that the drugmaker paid physicians illegal kickbacks to boost prescriptions of its pricey H.P. Acthar Gel, the U.S. Justice Department said.

The number of oncology treatments approved by the FDA has substantially increased in the past decade as part of an increasing effort to combat cancer, according to STAT.

Advertisement
Advertisement